Brian Pico, MD

Hematologist/Oncologist @MCIStrong @mhshospital | GU Oncology | Tweets are my own.

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Breaking news @ASCO #ASCO25 👉 1st biomarker selected, positive ph3 trial in mHSPC #ProstateCancer 👉Abiraterone+ niraparib/PARPi significant improve rPFS (favorable OS trend) in HRR+ pts (⬆️benefit in BRCApts), NGS testing must inall @AttardLab @PCF_Science @urotoday @OncoAlert

[Brian Rini, MD @brian_rini]

#ASCO25 Final results of IO-based combinations in mRCC are in! See below and subsequent posts for thoughts. Video discussing these data coming soon from @OncoAlert...

[Tom Powles @tompowles1]

The 5 yr follow up for adjuvant pembro in RCC (KN564): continued benefit- DFS (5yr 52% v61% - HR0.71) OS (5yr 82% vs 88% HR0.66). Maintained KM curve separation. No subgroup stands out. 18% TRAEs. Long term tox difficult to quantify but benifits seem to outweigh risks #ASCO25

[Yüksel Ürün @DrYukselUrun]

Adjuvant Pembrolizumab vs Placebo in ccRCC—5-year update is here.

🟢 DFS: 58.5% vs 48.7% → +9.8% absolute benefit
🟢 OS: 86.1% vs 79.4% → +6.7% absolute benefit
HR for OS: 0.66 | HR for DFS: 0.71
Benefit sustained beyond 5 years.
A milestone for adjuvant immunotherapy in RCC.

#ASCO25 #cancer #oncology
@oncoalert @ASCO @medicalwatchBC
@DrChoueiri @yekeduz_emre @neerajaiims @CParkMD @Silke_Gillessen @PGrivasMDPhD @VivekSubbiah @TwoOncDocs @OncBrothers @Larvol @nataliagandur @montypal @crisbergerot @DrDanielHeng
@TiansterZhang @HHammersMD @sonpavde @drenriquegrande @scserendipity1 @tompowles1 @BraunMDPhD @uromigos @MattGalsky @apolo_andrea
@bavilima @SuyogCancer @ONCOassist @gbanna74 @NazliDizman @MedicalwatchFTW @OncLive @urologysummit @IMG_Oncologists @AmandaBinDC @sarah_c_hopkins @MikeSerzanMD

[Oncology Brothers @OncBrothers]

Day 1 #ASCO25 highlights:

1. Review on recent approvals

2. #BREAKWATER (update): BRAF+ mCRC

3. #CM8HW (update): MSI-H mCRC

4. #DYNAMIC: ctDNA in colon ca

5. #CAIRO6: periOP Rx in peritoneal mets

#OncTwitter @ASCO

1/6

[Yüksel Ürün @DrYukselUrun]

PORTOS predicts RT dose benefit in localized prostate cancer! Shuang Zhao, MD
🧬☢️In two phase III trials (NRG/RTOG 0126 & SAKK 09/10), the 24-gene PORTOS score identified patients who benefited from radiation dose escalation.
@asco @oncoalert #GU25 #cancer #oncology @Mi@MikeSerzanMD @drenriquegrande @crisbergerot @reginabarcar @DRBakaloudiMD @abvilima @ReneeSaliby @yekeduz_emre @neerajaiims @DrChoueiri @montypal @PGrivasMDPhD @CParkMD @OncLive @amerseburger

[Tom Powles @tompowles1]

TALAPR02 looks at Talazoparib/enza vs enza in 1st line CRPC . It has significant OS in ITT HR=0.796. It’s current used in HRR deficient. Subset analysis and wider data still supports the HRR biomarker OS (HRR deficient HR -0.54, HRR non-defficent/NA 0.87), but ITT OS is +ve #GU25

[Dra. María Natalia Gandur Quiroga @nataliagandur]

💫🌟📝 Key findings from the pembrolizumab study in kidney cancer:
@OncoAlert @OncoReporte
🔬 First adjuvant therapy to improve overall survival in kidney cancer.

🧑‍🤝‍🧑 91% of patients on pembrolizumab alive at 4 years vs. 86% on placebo.

⏳ 40% reduction in the risk of death with pembrolizumab.

📈 FDA approved in 2021 based on improved recurrence-free survival.

@MSKCC_OncoNotes @Motzer @NCIResearchCtr @nciccr_gmb
🔖 #Oncology #KidneyCancer #Pembrolizumab #ASCO2024

👉 More info: NEJM

https://t.co/ouYpCShErZ

[Brian Pico, MD @BPicoMD]

Thank you @JavierRomerotv and @Univision23 for the invitation to discuss prostate cancer and the importance of early detection on their program, 'Contigo en la Comunidad'. Episode airs Saturday on Univisión.

@mhshospital

[Tom Powles @tompowles1]

Perhaps the most important long-term bladder cancer data #ASCO24 Neoadjuvant Toripalimab & disitimab Vedotin in muscle invasive bladder cancer (n=47). pCR ⬆️ 63%. 14% G3/4 AEs. All surgeries occurred . The 1st MMAE/IO neoadjuvant combo data looks ✅✅. EV/IO MIBC trials awaited

[Tom Powles @tompowles1]

DFF332 (HIF2a inhibitor) was tested in heavily pretreated RCC. 5% response rates and some stable disease. HIF biomaker looked unhelpful, but more to do here. Belzutifan seems more active as a single again #ASCO24 @montypal

[Dr. Luis E. Raez @LuisRaezMD]

FASCO awards at @ASCO with @eevokes @NarjustFlorezMD @DrChoueiri @EdgardoSantosMD @edgardo_ny @RManochakian @CharuAggarwalMD Pasi Janne and Raymond O. Mathew Gubbens and others! #lungcancer #lcsm #cancer

[Dr. Luis E. Raez @LuisRaezMD]

Celebrating our @ASCO FASCO designation with @NarjustFlorezMD @clarissamathias @CharuAggarwalMD Raymond O. @EdgardoSantosMD @RManochakian @edgardo_ny #lungcancer #lcsm several @IASLC members awarded today

[Brian Pico, MD @BPicoMD]

First two days of #ASCO24 have been stellar thus far. Over 40,000 in-person and virtual attendees who share a common goal. Nothing like it. Grateful to be here to collaborate and learn. @MCIStrong

[Brian Pico, MD @BPicoMD]

Proud to be an investigator of this first-in-human phase I clinical trial for multiplexed T-cell receptor engineered T-cell therapy (TCR-T) for solid tumors. Come check out our poster at #ASCO24 #ASCO @MCIStrong !

[Tom Powles @tompowles1]

Preliminary SURE1 data shows neoadjuvant sacituzumab govitecan (n=21) required dose changes & GCSF to overcome toxicity. 33% didn’t have surgery making having responded efficacy hard to interpret. The trial goes on. pCR and ctDNA suggest activity but not transformative #ASCO24

[Yüksel Ürün @DrYukselUrun]

Disappointing Results for Gilead’s Phase 3 TROPiCS-04 Study!
⭕️ Sacituzumab govitecan (Trodelvy)
in metastatic urothelial cancer did not meet the primary endpoint of overall survival.
⭕️Increased deaths due to neutropenic complications were noted in the Trodelvy group.
#Asco24 @BladderCancerUS @OncoAlert

https://t.co/RUIwjZdbVC

[FLORIDA @UF]

.@Forbes names the University of Florida a “New Ivy” — recognizing UF’s top-performing graduates and the university leading higher education's evolution.
https://t.co/Xso6nFfXUM

[Tom Powles @tompowles1]

With a median FU up of ~5 yrs adjuvant pembro= 38% reduction in risk of death. The benefit is across subgroups (T stage etc). Subsequent therapy in 80% is relapses. The 1st +ve OS adjuvant PD1 study, making adjuvant pembro more attractive. #GU24 @DrChoueiri

[Toni Choueiri, MD @DrChoueiri]

51 years in the making till #GU24. OS benefit in adjuvant Renal Cancer is finally here. #KYN564